Current standard care of therapies for lung adenocarcinoma involve molecular testing of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) at the initial diagnosis as multiple targeted therapies have already been approved for those subtypes of diseases with actionable mutations. Here, ALK is linked to lung adenocarcinoma.